Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 9Urinary Bladder Neoplasms 7Ureteral Neoplasms 3Muscle Invasive Bladder Urothelial Carcinoma 2Carcinoma, Renal Cell 2Advanced Bladder Cancer 2Urogenital Neoplasms 1Urachal adenocarcinoma 1Salivary Gland Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Penile Squamous Cell Carcinoma (PSCC) 1Penile Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Metastatic Castration-resistant Prostate Cancer 1Melanoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma, Adenoid Cystic 1

Interventions

pembrolizumab 1enfortumab vedotin 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Urachal adenocarcinoma × enfortumab vedotin × Clear all
NCT05756569 2025-07-28

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Emory University

Phase 2 Recruiting
25 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡